CANY
TXG icon

Caxton Associates (New York)’s 10x Genomics TXG Stock Holding History

Caxton Associates (New York)’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,551
Closed -$574K – 743
2022
Q1 		$574K Buy
+7,551
New +$661K 0.05% 213
2021
Q3 		– Sell
-1,893
Closed -$371K – 605
2021
Q2 		$371K Buy
+1,893
New +$343K 0.04% 247

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Caxton Associates (New York)'s TXG Position: Q2 2022 in Review

Caxton Associates (New York) sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 7,551 shares — an estimated $574K sold.

Caxton Associates (New York) first reported a position in TXG in Q2 2021 and held it in 2 quarters. The position peaked at $574K in Q1 2022. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

  • Caxton Associates (New York) reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 7,551 10x Genomics shares in Q2 2022, an estimated $574K.
  • Caxton Associates (New York) first reported a position in 10x Genomics in Q2 2021 and held it in 2 quarters.
  • Caxton Associates (New York)'s 10x Genomics position peaked at $574K in Q1 2022.
  • 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.